FINWIRES · TerminalLIVE
FINWIRES

ReNew Commissions Record 2.4 GW in FY2026, Becomes India's Second-Largest Renewable Operator

-- Indian firm ReNew Energy Global Plc commissioned approximately 2.4 gigawatts of renewable energy capacity in the fiscal year ended Mar. 31, its highest-ever annual addition, lifting its total operating portfolio to about 12.6 GW, the second-largest in India, the company said in a statement on Wednesday.

The figure reflects an adjustment for 600 megawatts of assets sold during the year. The newly commissioned capacity includes around 1.75 GW of solar, 0.62 GW of wind, and 25 MW/100 MWh of battery energy storage systems. The company added that roughly 450 MW of fully constructed capacity is expected to be commissioned soon. Its total gross capacity stood at about 20 GW at fiscal year-end.

ReNew, which has operated in India's clean energy sector for more than 15 years, continues to expand across both utility-scale and commercial and industrial segments. Its commercial and industrial arm, ReNew Green, has about 2.5 GW of committed capacity, with more than 2.0 GW already operational. The division counts major global firms, including Microsoft, Amazon, and Google, among its partners. In March 2026, ReNew Green secured $95 million in equity funding from a consortium led by LeapFrog Investments.

In solar manufacturing, ReNew reported 6.5 GW of module capacity and 2.5 GW of cell capacity currently in operation, with plans to expand cell capacity by an additional 4 GW by December 2026.

During FY2026, its facilities produced over 4.1 GW of modules and nearly 1.86 GW of cells. Earlier in the year, the manufacturing business received a $100 million equity investment from British International Investment.

The company operates more than 150 renewable energy sites and three solar manufacturing facilities across 10 Indian states, employing roughly 4,500 people. At its current operating capacity, ReNew said it generates enough clean energy to power approximately 24 million households and avoid about 23 million tonnes of carbon dioxide equivalent emissions annually.

相關文章

Asia

Dizal Pharma將在美國臨床腫瘤學會年會上發表三種藥物的研究成果。

根據週三在上海證券交易所發布的公告顯示,江蘇迪扎爾製藥(SHA:688192)表示,將在美國臨床腫瘤學會(ASCO)年會上公佈其新藥sunvozertinib片劑、golidocitinib膠囊和DZD6008的最新研究成果。 sunvozertinib和DZD6008皆用於治療非小細胞肺癌,而golidocitinib則用於治療T細胞淋巴瘤。研究結果顯示,這些藥物均取得了正面成果,尤其是DZD6008,其具有顯著的抗腫瘤活性且安全性良好。 該生技公司的股價在午盤交易中上漲不到2%。

$SHA:688192
Asia

Critica將於3月季度啟動西澳大利亞稀土計畫範圍界定研究。

根據週三提交給澳洲證券交易所的文件顯示,Critica(ASX:CRI)表示,位於西澳大利亞的Jupiter稀土計畫的初步研究已於今年3月季度正式啟動。 該研究整合了選礦、下游加工、基礎設施和開發假設,旨在確定一個基準開發路徑。 公司計劃在6月季度繼續完成Jupiter專案140個鑽孔的資源升級鑽探工作。此外,該公司還計劃準備並運送20,000公斤散裝樣品進行中試規模處理,以支援持續的最佳化、性能提升和中間精礦的生產。

$ASX:CRI
Asia

北太平洋銀行的收購要約確保了對卡里爾銀行的控制權

北太平洋銀行(東京證券交易所代號:8524)週三在東京證券交易所發佈公告稱,其對Career Bank的股份收購要約已獲成功,持股比例增至88.26%,使Career Bank成為其子公司。 北太平洋銀行此次收購了852,487股Career Bank股份,超過了完成交易所需的最低收購數量。 交易結算將於4月28日開始,屆時Career Bank將正式併入北太平洋銀行的財務報表。 北太平洋銀行計劃啟動相關程序,使Career Bank成為其全資子公司,並將其股票從札幌證券交易所下市。此次收購總成本約為15億日圓。

$TYO:8524